Analyst Price Target is $9.75
▲ +111.96% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for OmniAb in the last 3 months. The average price target is $9.75, with a high forecast of $13.00 and a low forecast of $6.00. The average price target represents a 111.96% upside from the last price of $4.60.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in OmniAb. This Buy consensus rating has held steady for over two years.
OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.